My Account
About Us
Contact us
الواجهة العربية
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »

Screening by Chest Radiograph and Lung Cancer Mortality: PLCO Randomized Trial

Screening by Chest Radiograph and Lung Cancer Mortality: PLCO Randomized Trial

Martin M. Oken, MD; Willam G. Hocking, MD; Paul A. Kvale, MD; Gerald L. Andriole, MD; Saundra S. Buys, MD; Timothy R. Church, PhD, MS; E. David Crawford, MD; Mona N. Fouad, MD; Claudine Isaacs, MD; Douglas J. Reding, MD, MPH; Joel L. Weissfeld, MD, PhD; Lance A. Yokochi, MD, PhD; Barbara O’Brien, MPH; Lawrence R. Ragard, MD; Joshua M. Rathmell, MS; Thomas L. Riley, BS; Patrick Wright, BS; Neil Caparaso, MD; Ping Hu, PhD; Grant Izmirlian, PhD; Paul F. Pinsky, PhD; Philip C. Prorok, PhD; Barnett S. Kramer, MD, MPH; Anthony B. Miller, MD; John K. Gohagan, PhD; Christine D. Berg, MD for the PLCO Project Team

The Journal of the American Medical Association,
306:17, October 26, 2011

Screening by Chest Radiograph and Lung Cancer Mortality: PLCO Randomized Trial

The effect on mortality of screening for lung cancer with modern chest radiographs is unknown.

To evaluate the effect on mortality of screening for lung cancer using radiographs in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Design, Setting, and Participants
Randomized controlled trial that involved 154 901 participants aged 55 through 74 years, 77 445 of whom were assigned to annual screenings and 77 456 to usual care at 1 of 10 screening centers across the United States between November 1993 and July 2001. The data from a subset of eligible participants for the National Lung Screening Trial (NLST), which compared chest radiograph with spiral computed tomographic (CT) screening, were analyzed.

Participants in the intervention group were offered annual posteroanterior view chest radiograph for 4 years. Diagnostic follow-up of positive screening results was determined by participants and their health care practitioners. Participants in the usual care group were offered no interventions and received their usual medical care. All diagnosed cancers, deaths, and causes of death were ascertained through the earlier of 13 years of follow-up or until December 31, 2009.

Main Outcome
Measures Mortality from lung cancer. Secondary outcomes included lung cancer incidence, complications associated with diagnostic procedures, and all-cause mortality.

Screening adherence was 86.6% at baseline and 79% to 84% at years 1 through 3; the rate of screening use in the usual care group was 11%. Cumulative lung cancer incidence rates through 13 years of follow-up were 20.1 per 10 000 person-years in the intervention group and 19.2 per 10 000 person-years in the usual care group (rate ratio [RR]; 1.05, 95% CI, 0.98-1.12). A total of 1213 lung cancer deaths were observed in the intervention group compared with 1230 in usual care group through 13 years (mortality RR, 0.99; 95% CI, 0.87-1.22). Stage and histology were similar between the 2 groups. The RR of mortality for the subset of participants eligible for the NLST, over the same 6-year follow-up period, was 0.94 (95% CI, 0.81-1.10).

Annual screening with chest radiograph did not reduce lung cancer mortality compared with usual care.

اضغط هنا للقراءة باللغة العربية

Prepared by: Dr. Houssam Al-Nahhas

Forgot your password

sign up

Consultants Corner

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Talal Sabouni


Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details